2018 Feb;41(2):258-266
L., alAbsi, M., Sung, B
The clinical implication: aggressive dose escalation in lower-BMI users is the tolerability problem, not the compound itself
Our findings revealed that patients with high SLC25A39 expression were more sensitive to Dihydrorotenone, Trametinib, Sapitinib, SCH772984, and Selumetinib, whereas patients with low SLC25A39 expression exhibited sensitivity to BMS-75480, Mitoxantrone, Gemcitabine, Irinotecan, and Talazoparib
Retatrutide may be suitable for adults who: Have a body mass index (BMI) of 27 or higher Struggle with weight management despite diet and exercise efforts Have type 2 diabetes Do not have a personal or family history of certain medical conditions or allergies Tirzepatide may be suitable for adults who: Have a BMI of 30 or higher BMI of 27 or higher with weight-related conditions, such as type 2 diabetes, high blood pressure, or high cholesterol Struggle with weight management, mainly if youve had limited success with diet and exercise alone Do not have personal or family histories of certain medical conditions or allergies Retatrutide and tirzepatide: FAQs Is retatrutide better than tirzepatide for weight loss
